Breast Cancer Market Research Report - Global Forecast To 2023

Breast Cancer Market Research Report - Global Forecast To 2023

ID: MRFR/Pharma/0870-HCRR | July, 2017 | Region: Global | 80 pages | Half-Cooked Research Reports

Breast Cancer Market Research Report, by types (invasive ductal carcinoma, invasive lobular carcinoma and other), by treatment (chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy), end users (hospital pharmacies, private pharmacies) – Global Forecast to 2023


Market scenario:


Brest cancer is type of cancer developed in breast tissue. Formation of lump in a breast, red patches on the skin are the some of the common symptoms of the breast cancer. Obesity, lack of physical exercise, overexposure to radiation and drinking alcohol are some of the risk factor for developing breast cancer. According to WHO, it is the second most common type of cancer in women. Every year 200,000 new cases are diagnosed worldwide and this number is continuously increasing. Prevalence of breast cancer is more common in developed countries compare with developing countries. Increasing number of females suffering from breast cancer is the major factor for the growth of market. Beside this adoption of unhealthy lifestyle, increasing female geriatric population, exposure to harmful radiation and increasing governmental initiatives also contributed in the growth of the market. As no absolute treatment is available there is a scope for developing the market across the world. While on other hand high cost of the treatment, adverse effects associated with the therapy and long approval time for the drugs are responsible for restraining the growth of the market.


The global breast cancer market is expected to grow at a CAGR of 9.2% during forecasted period 2017-2023.


Study objectives global breast cancer market



  • To provide the detail information about drivers and factors restraining the market growth

  • To provide the market growth map over the forecast period- 2017-2023

  • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global breast cancer market

  • To provide the graphs and analyze the market on various factors like- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide the trends and opportunities in global breast cancer market

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to main countries

  • To provide the overview of key players and their strategic profiles in the market and drawing a competitive landscape for the market


Intended Audience



  • Breast cancer drug manufacturers

  • Breast cancer drug suppliers

  • Research and Development (R&D) Companies

  • Government Research Laboratories

  • Independent Research Laboratories

  • Government and Independent Regulatory Authorities

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Figure 1- Global breast cancer market, by treatment

breast cancer market, by treatment


Sources- Annual reports, Press release, White paper, Company Presentation


 


Segmentation


Global breast cancer market is segmented on the basis of type into invasive ductal carcinoma, invasive lobular carcinoma and other. On the basis of treatment they are segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy and other. Chemotherapy is further segmented into antimetabolites, anthracyclines, taxanes and alkylating agents. Target therapy is further segmented into tyrosine kinase inhibitors and monoclonal antibodies Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors and others. On the basis of end users the market is segmented into hospital pharmacies, private pharmacies and other.


Regional analysis


On regional basis, global breast cancer market is dominated by America. Changing lifestyle and increasing prevalence of breast cancer in America has driven the growth of the market. America breast cancer market is followed by Europe. Technological advances, increased life expectancy and healthcare expenditure of people is responsible for the growth of this market in America and Europe. Asia Pacific is expecting a fastest growth for the market.


Key players for global breast cancer market


Pfizer (US), Novartis AG (Switzerland), Oncogenex (US), Apthera Inc (UK), BioNumerik Pharmaceuticals (US), Oncothyreon Inc (US), Astellas (Japan), Bipar Sciences (US), Puma Biotechnology (US), Sanofi S.A. (US), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc. (US), Bayer AG (Germany)


Market Assessment
Market Assessment breast cancer market


Sources- Annual reports, World Health Organization (WHO), White paper, Company Presentation, National Institutes of Health, The Leukemia & Lymphoma Society, American cancer society

The report for global breast cancer market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

TABLE OF CONTENTS

1    INTRODUCTION    

      1.1    DEFINITION    

      1.2    SCOPE OF STUDY    

            1.2.1    RESEARCH OBJECTIVE    

            1.2.2    ASSUMPTIONS & LIMITATIONS    

                1.2.2.1    ASSUMPTIONS    

                1.2.2.2    LIMITATIONS    

      1.3    MARKET STRUCTURE:    

2    RESEARCH METHODOLOGY    

      2.1    RESEARCH PROCESS:    

      2.2    PRIMARY RESEARCH    

      2.3    SECONDARY RESEARCH:    

3    MARKET DYNAMICS    

      3.1    DRIVERS    

      3.2    RESTRAINTS        

      3.3    OPPORTUNITIES    

      3.4    MACROECONOMIC INDICATORS    

4    MARKET FACTOR ANALYSIS    

      4.1    PORTERS FIVE FORCES MODEL    

      4.2    BARGAINING POWER OF SUPPLIERS    

      4.3    BARGAINING POWER OF BUYERS    

      4.4    THREAT OF NEW ENTRANTS    

      4.5    THREAT OF SUBSTITUTES    

      4.6    INTENSITY OF RIVALRY    

5.    GLOBAL BREAST CANCER MARKET, BY TYPE

      5.1    INVASIVE DUCTAL CARCINOMA

      5.2    INVASIVE LOBULAR CARCINOMA 

      5.3    OTHER

6.    GLOBAL BREAST CANCER MARKET, BY TREATMENT

      6.1    CHEMOTHERAPY

            6.1.1    ANTIMETABOLITES

            6.1.2    ANTHRACYCLINES

            6.1.3    TAXANES

            6.1.4    ALKYLATING AGENTS. 

      6.2    SURGERY & RADIATION THERAPY

      6.3    TARGETED THERAPY

            6.3.1    TYROSINE KINASE INHIBITORS 

            6.3.2    MONOCLONAL ANTIBODIES 

      6.4    BIOLOGIC THERAPY

      6.5    HORMONE THERAPY

            6.5.1    ESTROGEN-RECEPTOR MODULATORS (SERMS)

            6.5.2    AROMATASE INHIBITORS 

            6.5.3    OTHERS

7.    GLOBAL BREAST CANCER MARKET, BY END USER

      7.1    HOSPITAL PHARMACIES

      7.2    PRIVATE PHARMACIES 

      7.3    OTHER

8.     GLOBAL BREAST CANCER MARKET, BY REGION

      8.1    INTRODUCTION

      8.2    AMERICA

            8.2.1    NORTH AMERICA

                8.2.1.1 US

                8.2.1.2 CANADA

            8.2.2    SOUTH AMERICA

      8.3    EUROPE

            8.3.1    WESTERN EUROPE

                8.3.1.1 GERMANY

                8.3.1.2 FRANCE

                8.3.1.3 ITALY

                8.3.1.3 SPAIN

                8.3.1.5 UK

                8.3.1.6 REST OF WESTERN EUROPE

            8.3.2    EASTERN EUROPE

      8.4    ASIA-PACIFIC

            8.4.1    JAPAN

            8.4.2    CHINA

            8.4.3    INDIA

            8.4.4    AUSTRALIA

            8.4.5    REPUBLIC OF KOREA

            8.4.6    REST OF ASIA-PACIFIC

      8.5    MIDDLE EAST & AFRICA

            8.5.1    UNITED ARAB EMIRATES

            8.5.2     SAUDI ARABIA

            8.5.3    OMAN

            8.5.4    KUWAIT

            8.5.5    QATAR

            8.5.6    REST OF MIDDLE EAST & AFRICA

9.    COMPETITIVE LANDSCAPE    

      9.1    MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS    

            9.1.1    STRATEGIC PARTNERSHIP    

            9.1.2    MERGER & ACQUISITION    

10    COMPANY PROFILE    

      10.1    PFIZER

            10.1.1    OVERVIEW    

            10.1.2    PRODUCT OVERVIEW    

            10.1.3    FINANCIALS    

            10.1.4    KEY DEVELOPMENTS    

      10.2    NOVARTIS AG

            10.2.1    OVERVIEW    

            10.2.2    PRODUCT OVERVIEW    

            10.2.3    FINANCIALS    

            10.2.4    KEY DEVELOPMENTS    

      10.3    F. HOFFMANN-LA ROCHE

            10.3.1    OVERVIEW

            10.3.2    PRODUCT OVERVIEW    

            10.3.3    FINANCIALS

            10.3.4    STRATEGY    

            10.3.5    KEY DEVELOPMENT    

      10.4    ASTRAZENECA

            10.4.1    OVERVIEW

            10.4.2    PRODUCT OVERVIEW

            10.4.3    FINANCIALS

            10.4.4    KEY DEVELOPMENTS    

      10.5     GLAXOSMITHKLINE

            10.5.1    OVERVIEW

            10.5.2    PRODUCT OVERVIEW    

            10.5.3    FINANCIALS    

            10.5.4    KEY DEVELOPMENTS    

      10.6    SUN PHARMACEUTICAL INDUSTRIES LTD

            10.6.1    OVERVIEW

            10.6.2    PRODUCT OVERVIEW

            10.6.3    FINANCIALS

            10.6.4    KEY DEVELOPMENTS    

      10.7     TEVA PHARMACEUTICAL INDUSTRIES

            10.7.1    OVERVIEW

            10.7.2    PRODUCT OVERVIEW    

            10.7.3    FINANCIALS    

            10.7.4    KEY DEVELOPMENTS    

      10.8    OTHERS 

11       CONCLUSION

      12.1    KEY FINDINGS

            12.1.1    FROM CEO’S VIEWPOINT 

            12.1.2    UNMET NEEDS OF THE MARKET 

      12.2    KEY COMPANIES TO WATCH

      12.3    PREDICTION OF ONCOCARE INDUSTRY

13        APPENDIX